查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年脑瘫治疗的全球市场
市场调查报告书
商品编码
1272770

2023-2030 年脑瘫治疗的全球市场

Global Cerebral Palsy Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球脑瘫治疗市场预计将实现利润丰厚的增长，到 2022 年将达到 32.074 亿美元，到 2030 年将达到 42.805 亿美元。 全球脑瘫治疗市场预计在预测期内（2023-2030 年）的复合年增长率为 3.7%。 主要参与者正在采取合作伙伴关係、合併、收购和地域扩张等战略，以在脑瘫治疗市场中脱颖而出，成为强大的竞争对手。 新产品的发布和对研发的更多关注是领先公司增加市场影响力的其他一些方式。

例如，2021 年 8 月 31 日，Merz Group 的一个部门宣布使用 XEOMIN 缓解体重低于 12 公斤的儿童和青少年因神经或神经发育障碍引起的慢性流涎症状。在欧盟层面，由神经毒素领域的先驱 Merz Therapeutics 提供。

脑瘫 (CP) 是一组以身体僵硬和运动障碍为特征的非进行性慢性疾病。 当大脑在子宫内发育不正常或出生后发生损伤时，就会出现这种情况。 它影响四肢的运动功能，导致平衡障碍、肌肉收缩、不协调和其他神经系统症状。

最常见的脑瘫类型是痉挛型、共济失调型和混合型。 治疗包括药物、疗法、手术和其他改善日常功能的治疗。 脑瘫无法治愈。

此外，脑瘫患病率的增加、临床试验的快速进行以及政府资金和企业投资的增加是预计在预测期内推动市场增长的关键因素。

市场动态

早产患病率上升推动全球脑瘫治疗市场增长

早产、低出生体重、多胞胎和妊娠期感染导致脑瘫病例增加。 据估计，每年有 1500 万婴儿早产，其中超过十分之一属于此类。 每年有超过 100 万儿童死于早产并发症。 许多倖存者可能面临终生残疾，例如学习障碍以及视力和听力障碍。

此外，甲状腺疾病、癫痫发作和智力障碍等孕产妇健康问题也可能引发儿童脑瘫。 此外，脑瘫治疗市场的快速增长归因于脑瘫发病率的增加、家长对脑瘫并发症的认识提高以及市场上各种治疗方案的可用性。人们认为。

例如，根据美国疾病控制和预防中心的数据，美国每 1,000 名儿童中就有 1.5 到 4 名患有脑瘫。 这种情况是由控制运动、姿势和平衡的大脑区域发育异常或受损引起的。 脑瘫最常发生在出生前，但也可能在出生时或出生后不久出现困难。 因此，由于上述因素，预计脑瘫治疗市场将在预测期内获得牵引力。

脑瘫治疗市场的增长受到药物急性副作用的阻碍

药物是脑瘫治疗的重要组成部分，有助于控制症状和改善生活质量，但它们也可能有副作用。 例如，肌肉鬆弛剂会导致嗜睡和疲劳，影响人的日常生活活动，并影响学校或工作。

此外，解痉药在用于治疗脑瘫时会引起胃肠道问题，例□□如便秘、腹泻和腹胀。 因此，由于上述因素，预计预测期内脑瘫治疗市场将受到阻碍。

COVID-19 影响分析

COVID-19 对脑瘫治疗市场产生了重大影响。 医疗机构优先考虑 COVID-19 患者，导致非紧急护理的延误和取消。 大流行减少了获得医疗保健服务的机会，使脑瘫患者更难获得所需的护理。

此外，大流行还扰乱了药品和医疗设备的供应链，使医护人员更难治疗脑瘫患者。 同样，它影响了用于治疗脑瘫的药物的开发、生产和分配，包括临床试验的延误。

另一方面，由于难以直接到医疗机构就诊，远程医疗服务正在普及，但目前的情况是，它们不一定能替代脑瘫患者面对面的医疗服务。

俄乌衝突分析

俄罗斯入侵乌克兰造成了一场人道主义危机，对智障人士及其家人造成了不成比例的影响。 孤儿院的残疾儿童因缺乏活动和痉挛性脑瘫治疗而变得扭曲和抽筋，因此慈善机构定期提供止痛治疗。 同样，全球儿童基金会在乌克兰的合作伙伴正在帮助残疾儿童及其家人撤离到更安全的地区并获得所需的物资。 因此，衝突对全球脑瘫治疗市场产生了一定影响。

人工智能影响分析

AI 系统改进了脑瘫儿童的预后并支持管理选择。 例如，斯坦福大学和明尼苏达州吉列儿童专科医院的研究人员使用人工智能和单个摄像头拍摄的视频来分析被诊断为脑瘫患者的运动障碍。 该系统价格低廉、易于使用且开源，使医生能够更好地识别、衡量进展并治疗神经和肌肉骨骼疾病。

内容

第一章调查方法及范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按药物类型分类的片段
  • 疾病片段
  • 按销售渠道分类的摘要
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 早产患者的增加推动了预测期内脑瘫治疗市场的增长
    • 约束因素
      • 药物的急性副作用将在预测期内阻碍脑瘫治疗市场的增长
    • 机会
      • 合作研究的增加
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌衝突分析

第8章人工智能的影响分析

第9章按药物类型分类

  • 抗惊厥药
  • 抗胆碱药
  • 抗抑郁药
  • 其他

第 10 章按疾病类型分类

  • 痉挛性脑瘫
  • 混合性脑瘫
  • 运动障碍性脑瘫
  • 共济失调性脑瘫

第 11 章分销渠道

  • 医院药房
  • 零售店和配药店
  • 在线药店

第12章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第13章竞争格局

  • 竞争场景
  • 产品基准
  • 公司股票分析
  • 主要发展和战略

第14章公司简介

  • Merz Pharmaceuticals, LLC。
    • 公司概况
    • 产品组合和说明
    • 财务摘要
    • 主要发展状况
  • Pfizer Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Novartis
  • AbbVie Inc.
  • Par Pharmaceutical
  • Hikma Pharmaceuticals Plc.

第15章 附录

简介目录
Product Code: PH4902

Market Overview

The global cerebral palsy treatment market reached US$ 3,207.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,280.5 million by 2030. The global cerebral palsy treatment market is expected to exhibit a CAGR of 3.7% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, and regional expansion to stand out as strong competitors in the cerebral palsy treatment market. Novel product launches and enhanced focus on research and development are some of the other ways where the leading players can improve their market presence.

For instance, on August 31, 2021, the use of XEOMIN for the relief of symptoms of chronic sialorrhea caused by neurological or neurodevelopmental disorders in children and adolescents weighing less than 12 kg has been approved on an EU level for Merz Therapeutics, a division of the Merz Group and a pioneer in the field of neurotoxins.

Cerebral Palsy (CP) is a collection of non-progressive, chronic illnesses marked by stiffness and mobility disability. It arises when the brain does not develop normally in the womb or due to a post-natal injury. It can affect motor function in all four limbs, resulting in balance issues, muscular contracture, coordination issues, and other neurological symptoms.

The most common cerebral palsy is spastic, ataxic dyskinetic, and mixed. Treatment options include medications, therapies, surgical procedures, and other treatments to improve daily functioning. There is no cure for cerebral palsy.

Furthermore, the increasing prevalence of cerebral palsy disorder, rapid clinical trials, and increasing government funding and company investments are key factors expected to drive the market growth over the forecast period.

Market Dynamics

The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth

Premature birth, low birth weight, multiple childbirths, and infectious diseases during pregnancy can lead to a rise in cerebral palsy cases. An estimated 15 million babies are born prematurely yearly, with more than one out of every ten falling under this category. Every year, over one million children die due to premature birth complications. Many survivors may face obstacles for the rest of their life, such as learning disabilities and visual and hearing problems.

Moreover, health problems in the mother, such as thyroid illness, seizures, intellectual impairment, and so on, might induce cerebral palsy in the kid. In addition, the rapid growth of the cerebral palsy treatment market can be attributed to an increase in the incidence of cerebral palsy and an increase in parental awareness of cerebral palsy complications, and the availability of various treatment options in the market.

For instance, according to the Centres for Disease Control and Prevention, 1.5 to 4 children out of every 1000 in the United States have cerebral palsy. The condition is caused by aberrant development or injury to brain regions that govern movement, posture, and balance. Cerebral palsy is most frequent before birth, but difficulties can arise during or immediately after birth. Thus, from the above factors, the cerebral palsy treatment market is expected to drive over the forecast period.

Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market

Medications are an important part of cerebral palsy treatment, helping to manage symptoms and improve quality of life, but can also have side effects. For instance, muscle relaxants can cause drowsiness and fatigue, which can affect a patient's ability to perform daily activities and interfere with their school or work.

Similarly, antispasmodics can cause gastrointestinal disturbances when used to treat cerebral palsy, such as constipation, diarrhea, and bloating. Hence, owing to the above factors, the cerebral palsy treatment market is expected to be hampered over the forecast period.

COVID-19 Impact Analysis

COVID-19 has had a significant impact on the cerebral palsy treatment market. Healthcare facilities have prioritized COVID-19 patients, leading to delays or cancellations of non-emergency treatments. The pandemic has caused reduced access to healthcare services, making it more difficult for patients with cerebral palsy to access the care they need.

Moreover, the pandemic has disrupted supply chains for medications and medical equipment, making it more difficult for healthcare providers to treat patients with cerebral palsy. Likewise, it had a sign on the development, production, and distribution of drugs used to treat cerebral palsy, including delayed clinical trials.

In contrast, telemedicine services have become increasingly popular due to the difficulty of visiting healthcare facilities in person, but it is not always a substitute for in-person care for patients with cerebral palsy.

Russia-Ukraine Conflict Analysis

Russia's invasion of Ukraine has caused a humanitarian crisis, disproportionately impacting people with intellectual disabilities and their families. Children in orphanages with disabilities had become twisted and constricted due to lack of activity and treatment for spastic cerebral palsy, so charitable organizations provided regular treatments to reduce pain. Similarly, global fund for Children partners in Ukraine is helping children with disabilities and their families evacuate to safer areas and get essential supplies. Therefore, the conflict has had a moderate impact on the global cerebral palsy treatment market.

Artificial Intelligence Impact Analysis

AI systems help to refine prognosis and assist in management selection for children with cerebral palsy. For instance, researchers at Stanford and Gillette Children's Specialty Hospital in Minnesota have used artificial intelligence and video shot with a single camera to analyze movement impairment in people diagnosed with cerebral palsy. This system is inexpensive, easy to use, and open-source, allowing doctors to better identify, measure progress, and treat neurological and musculoskeletal disorders.

Segment Analysis

The global cerebral palsy treatment market is segmented based on drug type, disease type, distribution channel, and region.

The spastic cerebral palsy segment is expected to hold a dominant position in the market over the forecast period

The spastic cerebral palsy segment accounted for the highest market stake accounting for approximately 70.4% of the cerebral palsy treatment market in 2022. Spastic cerebral palsy is a developmental disorder caused by brain damage before birth, during delivery, or in the first few years of life. Children are the most affected and develop co-occurring symptoms, driving revenue growth in this segment.

Spastic CP, such as quadriplegia, hemiplegia, and diplegia, affects the body the most. Treatment options such as physical therapy, medication, baclofen pump, spine or cord surgery, muscle release, and tendon lengthening surgery are used to prevent symptoms, creating demand for this segment.

Moreover, companies such as Merz Pharmaceuticals, Teva Pharmaceuticals, Supernus Pharmaceuticals, and Rohto Pharmaceutical are conducting clinical trials to explore new treatment options, driving revenue growth.

Geographical Analysis

The increasing prevalence of cerebral palsy disorder, and increasing funding by government organizations to dominate the North America region

North America is expected to dominate the worldwide cerebral palsy treatment market, accounting for around 2/5th of this market, with the U.S. being the major contributor. For instance, the U.S. government offers a variety of financial benefits to people with cerebral palsy, such as benefit programs, scholarships, grants, and subsidized loans. The most common resources are Supplemental Security Income (SSI), the Individuals With Disabilities Education Act (IDEA), and Medicaid.

Competitive Landscape

The major global players in the market include Merz Pharmaceuticals, LLC., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, and Hikma Pharmaceuticals Plc among others.

Why Purchase the Report?

  • To visualize the global cerebral palsy treatment market segmentation based on the drug type, disease type, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cerebral palsy treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global cerebral palsy treatment market report would provide approximately 61 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Disease Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth during the forecast period.
    • 4.1.2. Restraints
      • 4.1.2.1. Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market in the forecast period.
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing collaborative research efforts
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Artificial Intelligence Impact Analysis

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Anticonvulsants*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Anticholinergics
  • 9.4. Antidepressants
  • 9.5. Other

10. By Disease Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.1.2. Market Attractiveness Index, By Disease Type
  • 10.2. Spastic Cerebral Palsy*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Mixed Cerebral Palsy
  • 10.4. Dyskinetic Cerebral Palsy
  • 10.5. Ataxic Cerebral Palsy

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail stores and Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Merz Pharmaceuticals, LLC. *
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Pfizer Inc.
  • 14.3. Viatris Inc.
  • 14.4. Teva Pharmaceutical Industries Ltd.
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. GlaxoSmithKline plc.
  • 14.7. Novartis
  • 14.8. AbbVie Inc.
  • 14.9. Par Pharmaceutical
  • 14.10. Hikma Pharmaceuticals Plc.

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us